These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16809268)

  • 1. Effects of erythropoietin treatment on cell-mediated immune responses in predialysis patients.
    Hannula P; Ala-Houhala I; Saha H; Lagerstedt A; Parviainen T; Pasternack A; Antonen J
    Scand J Urol Nephrol; 2006; 40(3):241-6. PubMed ID: 16809268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
    Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD.
    Siamopoulos KC; Gouva C; Katopodis KP; Tzallas C; Nikolopoulos P; Papavasiliou EC; Tselepis AD
    Am J Kidney Dis; 2006 Aug; 48(2):242-9. PubMed ID: 16860190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin enhances immune responses in mice.
    Katz O; Gil L; Lifshitz L; Prutchi-Sagiv S; Gassmann M; Mittelman M; Neumann D
    Eur J Immunol; 2007 Jun; 37(6):1584-93. PubMed ID: 17458859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of erythropoietin on lymphocyte and granulocyte functions in dialyzed patients].
    Bartůnková J; Fucíková T; Sulková S; Marecková H
    Cas Lek Cesk; 1989 Oct; 128(42):1332-5. PubMed ID: 2598245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
    Krapf R; Hulter HN
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
    van der Putten K; Braam B; Jie KE; Gaillard CA
    Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients.
    Vacher-Coponat H; Brunet C; Lyonnet L; Bonnet E; Loundou A; Sampol J; Moal V; Dussol B; Brunet P; Berland Y; Dignat-George F; Paul P
    Nephrol Dial Transplant; 2008 Apr; 23(4):1406-14. PubMed ID: 18029366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients.
    Zadrazil J; Horák P; Horcicka V; Zahálková J; Strébl P; Hrubý M
    Kidney Blood Press Res; 2007; 30(2):108-16. PubMed ID: 17374961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.